ArticlePharmacoEconomics2011

Adjuvant trastuzumab for breast cancer: uncertainties in clinical and economic evidence following early stopping of the HERA trial.

Tallal Younis et al.PubMed ↗Publisher ↗

No numbers read from the abstract.